AstraZeneca stock falls as investors balk at reported Bristol Myers tie-up
AstraZeneca shares dropped as a lot as 7% on Monday after experiences that the corporate had discussed a potential mega-merger with Bristol Myers Squibb, a deal that analysts mentioned can be a stunning strategic transfer for one of many pharmaceutical trade’s strongest development tales. If accomplished, a deal may worth the businesses at roughly $400…